Follow the Ajanta Pharma share price and the full insider trade history of the company, a listed equity based in India. Shares are listed on IN IN, under the authority of SEBI (PIT + SAST). Market capitalisation: €422.3bn. The latest transaction was filed on 14 July 2026 (Pledge). Among the most active insiders: Ravi P Agrawal, trustee Ravi Agrawal Trust. Every trade is free.
12
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€93m
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Ajanta Pharma Buy (bullish), based on 12 analysts. Average price target: ₹3,207.58.
22Σ signal
Buys n/a€93m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 8,889 of 27,967 companies
60.6
score / 100
Value
34
Quality
88
FCF yld0.4%
Earn yld2.4%
EV/EBITDA28.3x
ROE·
Gross mgn77%
Net mgn20%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Ajanta Pharma is an Indian pharmaceutical company specializing in the manufacturing of generic drugs and healthcare products. It is listed on the Bombay Stock Exchange.